SCHEDULE 13G/A: Venrock Healthcare Capital Partners Amends Passive Stake in Trevi Therapeutics, Reporting 1.4% Ownership
Beneficial Ownership Amendment
Venrock Healthcare Capital Partners and its affiliated entities have filed an amended Schedule 13G, disclosing a 1.4% beneficial ownership stake in Trevi Therapeutics, Inc. as of December 31, 2024.
Summary
- This document is Amendment No. 4 to a Schedule 13G filing by a group of entities and individuals associated with Venrock Healthcare Capital Partners regarding their beneficial ownership of Trevi Therapeutics, Inc. Common Stock.
- As of December 31, 2024, the reporting group collectively beneficially owns 1,266,457 shares of Trevi Therapeutics, Inc. Common Stock.
- This ownership represents 1.4% of the total outstanding Common Stock of Trevi Therapeutics, Inc.
- The percentage is calculated based on 76,865,711 shares outstanding as of October 31, 2024, plus an additional 12,500,000 shares issued in a public offering described in a December 15, 2024 prospectus supplement, totaling 89,365,711 shares.
- The reporting persons explicitly state that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing passive ownership. It contains factual information about shareholdings and does not express positive or negative sentiment about the issuer's performance or prospects.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Trevi Therapeutics, Inc.'s future operations or financial performance.
Industry Context
This filing pertains to an investment in Trevi Therapeutics, Inc., a company operating within the biotechnology or pharmaceutical sector, as indicated by the nature of the 'Healthcare Capital Partners' investor group. The filing itself is a standard regulatory disclosure of passive ownership by an institutional investor group.
Stakeholder Impact
- This filing primarily impacts shareholders by providing transparency on the ownership structure of a significant institutional investor group. A decrease in reported ownership percentage might be viewed differently by various shareholders.
Key Dates
| Date | Description |
|---|---|
| 2022-04-21 | Date of original Schedule 13G filing for Power of Attorney exhibits referenced in this amendment. |
| 2024-10-31 | Date of shares outstanding reported in Issuer's Quarterly Report on Form 10-Q. |
| 2024-11-06 | Date Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2024-12-15 | Date of Issuer's prospectus supplement describing a public offering. |
| 2024-12-16 | Date Issuer's prospectus supplement was filed with the SEC. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-02-14 | Date of execution and filing of this Schedule 13G/A and Joint Filing Agreement. |
Keywords
Trevi Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G/A, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Passive Investment, Biotechnology, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.